Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats

Journal of Hepatology

Volumn 49, Issue 3, 2008, Pages 417-428

  Wei, Yongzhong ^a   Clark, Suzanne E ^a   Morris, E Matthew ^a   Thyfault, John P ^a,b   Uptergrove, Grace M E ^a   Whaley Connell, Adam T ^a   Ferrario, Carlos M ^c   Sowers, James R ^a,b   Ibdah, Jamal A ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Non alcoholic fatty liver disease; Oxidative stress

Indexed keywords

ANGIOTENSIN II; RENIN; TEMPOL; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; DISEASE COURSE; FATTY LIVER; FIBROSIS; LIPID PEROXIDATION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; TRANSGENIC RAT;

ANGIOTENSIN II; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; APOPTOSIS; BLOOD PRESSURE; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; FATTY LIVER; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIN LABELS; TETRAZOLES; VALINE;

EID: 48449097273     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.03.018     Document Type: Article

References (38)

1. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 1649-1657
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
3. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., and Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
4. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
5. Friedman S.L., and Bansal M.B. Reversal of hepatic fibrosis - fact or fantasy?. Hepatology 43 (2006) S82-S88
6. Mato J.M., and Lu S.C. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology 45 (2007) 1306-1312
7. Shimada M., Hashimoto E., Taniai M., Hasegawa K., Okuda H., Hayashi N., et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37 (2002) 154-160
8. Adams L.A., Lymp J.F., St. Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
9. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2 (2004) 1048-1058
10. Newberry E.P., Xie Y., Kennedy S., Han X., Buhman K.K., Luo J., et al. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem 278 (2003) 51664-51672
11. Sowers J.R. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 346 (2002) 1999-2001
12. Helmy A., Jalan R., Newby D.E., Hayes P.C., and Webb D.J. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 118 (2000) 565-572
13. Powell E.E., Edwards-Smith C.J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31 (2000) 828-833
14. Hirose A., Ono M., Saibara T., Nozaki Y., Masuda K., Yoshioka A., et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45 (2007) 1375-1381
15. Ohishi T., Saito H., Tsusaka K., Toda K., Inagaki H., Hamada Y., et al. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res 21 (2001) 147-158
16. Ueki M., Koda M., Yamamoto S., Matsunaga Y., and Murawaki Y. Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 41 (2006) 996-1004
17. Kopkan L., Kramer H.J., Huskova Z., Vanourkova Z., Skaroupkova P., Thurmova M., et al. The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens 23 (2005) 1531-1539
18. Peters J., Munter K., Bader M., Hackenthal E., Mullins J.J., and Ganten D. Increased adrenal renin in transgenic hypertensive rats, TGR(mREN2)27, and its regulation by cAMP, angiotensin II, and calcium. J Clin Invest 91 (1993) 742-747
19. Zhao Y., Bader M., Kreutz R., Fernandez-Alfonso M., Zimmermann F., Ganten U., et al. Ontogenetic regulation of mouse Ren-2d renin gene in transgenic hypertensive rats, TGR(mREN2)27. Am J Physiol 265 (1993) E699-E707
20. Mullins J.J., Peters J., and Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344 (1990) 541-544
21. Ibdah J.A., Perlegas P., Zhao Y., Angdisen J., Borgerink H., Shadoan M.K., et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 128 (2005) 1381-1390
22. Lee M.A., Bohm M., Paul M., Bader M., Ganten U., and Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 270 (1996) E919-E929
23. Tilg H., and Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343 (2000) 1467-1476
24. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., and Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006) 27-33
25. Bataller R., Schwabe R.F., Choi Y.H., Yang L., Paik Y.H., Lindquist J., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112 (2003) 1383-1394
26. Garcia-Pagan J.C., Bosch J., and Rodes J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 6 (1995) 140-147
27. Bataller R., Sancho-Bru P., Gines P., Lora J.M., Al-Garawi A., Sole M., et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125 (2003) 117-125
28. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34 (2001) 745-750
29. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 (2005) 209-218
30. Yang L., Bataller R., Dulyx J., Coffman T.M., Gines P., Rippe R.A., et al. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 43 (2005) 317-323
31. Ferret P.J., Hammoud R., Tulliez M., Tran A., Trebeden H., Jaffray P., et al. Detoxification of reactive oxygen species by a nonpeptidyl mimic of superoxide dismutase cures acetaminophen-induced acute liver failure in the mouse. Hepatology 33 (2001) 1173-1180
32. Malassagne B., Ferret P.J., Hammoud R., Tulliez M., Bedda S., Trebeden H., et al. The superoxide dismutase mimetic MnTBAP prevents Fas-induced acute liver failure in the mouse. Gastroenterology 121 (2001) 1451-1459
33. Brasier A.R., Recinos III A., and Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22 (2002) 1257-1266
34. Muller D.N., Dechend R., Mervaala E.M., Park J.K., Schmidt F., Fiebeler A., et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35 (2000) 193-201
35. Guicciardi M.E., and Gores G.J. Apoptosis: a mechanism of acute and chronic liver injury. Gut 54 (2005) 1024-1033
36. Bataller R., Gabele E., Schoonhoven R., Morris T., Lehnert M., Yang L., et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 285 (2003) G642-G651
37. Bataller R., Gabele E., Parsons C.J., Morris T., Yang L., Schoonhoven R., et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41 (2005) 1046-1055
38. Zamara E., Novo E., Marra F., Gentilini A., Romanelli R.G., Caligiuri A., et al. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 40 (2004) 60-68